{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Myelodysplastic+Syndromes&page=3&q=lower-risk+MDS",
    "query": {
      "q": "lower-risk MDS",
      "condition": "Myelodysplastic Syndromes",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 104,
    "total_pages": 11,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Myelodysplastic+Syndromes&page=4&q=lower-risk+MDS&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Myelodysplastic+Syndromes&page=2&q=lower-risk+MDS&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-10T01:25:19.034Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00217594",
      "title": "A Pilot Study of Alemtuzumab (Campath[R]) in Patients With Myelodysplastic Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myelodysplastic Syndromes"
      ],
      "interventions": [
        {
          "name": "Alemtuzumab (Campath)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "72 Years",
        "sex": "ALL",
        "summary": "18 Years to 72 Years"
      },
      "enrollment_count": 40,
      "start_date": "2005-07-21",
      "completion_date": "2017-02-06",
      "has_results": true,
      "last_update_posted_date": "2018-10-30",
      "last_synced_at": "2026-10-10T01:25:19.034Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00217594"
    },
    {
      "nct_id": "NCT00467961",
      "title": "Stem Cell Transplantation for Patients With Cancers of the Blood",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "CML (Chronic Myelogenous Leukemia)",
        "CLL (Chronic Lymphocytic Leukemia)",
        "AML (Acute Myelogenous Leukemia)",
        "Acute Lymphocytic Leukemia",
        "MDS (Myelodysplastic Syndrome)"
      ],
      "interventions": [
        {
          "name": "Miltenyi system",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 61,
      "start_date": "2007-04",
      "completion_date": "2012-11",
      "has_results": true,
      "last_update_posted_date": "2018-07-13",
      "last_synced_at": "2026-10-10T01:25:19.034Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00467961"
    },
    {
      "nct_id": "NCT02807558",
      "title": "A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "Tamibarotene",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine",
          "type": "DRUG"
        },
        {
          "name": "Daratumumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Syros Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 155,
      "start_date": "2016-09-20",
      "completion_date": "2023-01-25",
      "has_results": true,
      "last_update_posted_date": "2024-12-13",
      "last_synced_at": "2026-10-10T01:25:19.034Z",
      "location_count": 14,
      "location_summary": "Hartford, Connecticut • Miami, Florida • Iowa City, Iowa + 11 more",
      "locations": [
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02807558"
    },
    {
      "nct_id": "NCT01566695",
      "title": "The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "Oral Azacitidine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Best Supportiv Care (BSC)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 216,
      "start_date": "2013-04-26",
      "completion_date": "2023-12-21",
      "has_results": true,
      "last_update_posted_date": "2025-01-07",
      "last_synced_at": "2026-10-10T01:25:19.034Z",
      "location_count": 40,
      "location_summary": "Berkeley, California • Beverly Hills, California • Duarte, California + 31 more",
      "locations": [
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Escondido",
          "state": "California"
        },
        {
          "city": "Greenbrae",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01566695"
    },
    {
      "nct_id": "NCT05732961",
      "title": "Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myelodysplastic Syndromes",
        "Myeloproliferative Neoplasm",
        "Anemia"
      ],
      "interventions": [
        {
          "name": "Luspatercept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2023-02-21",
      "completion_date": "2026-09",
      "has_results": false,
      "last_update_posted_date": "2026-05-05",
      "last_synced_at": "2026-10-10T01:25:19.034Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05732961"
    },
    {
      "nct_id": "NCT00533923",
      "title": "Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "AML",
        "ALL",
        "CLL",
        "Myelodysplastic Syndrome",
        "Non-Hodgkin's Lymphoma",
        "Hodgkin's Lymphoma",
        "Multiple Myeloma",
        "Aplastic Anemia",
        "Myeloproliferative Disorder"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide; Fludarabine; Cyclosporin; CAMPATH-1H (Alemtuzumab); GM-CSF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Beth Israel Deaconess Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "Up to 65 Years"
      },
      "enrollment_count": 25,
      "start_date": "2002-12",
      "completion_date": "2007-01",
      "has_results": false,
      "last_update_posted_date": "2016-07-18",
      "last_synced_at": "2026-10-10T01:25:19.034Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00533923"
    },
    {
      "nct_id": "NCT07579429",
      "title": "Research On Nicotinamide Riboside Supplement Support in MDS (ROSS Trial)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Clonal Cytopenia of Undetermined Significance",
        "Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "Nicotinamide Riboside",
          "type": "DRUG"
        },
        {
          "name": "Pterostilbene",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2026-05-20",
      "completion_date": "2030-12-18",
      "has_results": false,
      "last_update_posted_date": "2026-06-03",
      "last_synced_at": "2026-10-10T01:25:19.034Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07579429"
    },
    {
      "nct_id": "NCT02143830",
      "title": "HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Fanconi Anemia",
        "Severe Marrow Failure",
        "Myelodysplastic Syndrome (MDS)",
        "Acute Myelogenous Leukemia (AML)"
      ],
      "interventions": [
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "rabbit ATG",
          "type": "DRUG"
        },
        {
          "name": "G-CSF",
          "type": "DRUG"
        },
        {
          "name": "Peripheral blood stem cell",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Children's Hospital Medical Center, Cincinnati",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Months",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "3 Months and older"
      },
      "enrollment_count": 70,
      "start_date": "2014-04",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2025-11-12",
      "last_synced_at": "2026-10-10T01:25:19.034Z",
      "location_count": 3,
      "location_summary": "New York, New York • Cincinnati, Ohio • Seattle, Washington",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02143830"
    },
    {
      "nct_id": "NCT02269280",
      "title": "Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "Azacitidine (AZA) Days 1 - 3",
          "type": "DRUG"
        },
        {
          "name": "Decitabine (DAC)",
          "type": "DRUG"
        },
        {
          "name": "Best Supportive Care (BSC)",
          "type": "OTHER"
        },
        {
          "name": "Azacitidine (AZA) Days 1 - 5",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 185,
      "start_date": "2014-10-13",
      "completion_date": "2024-07-25",
      "has_results": true,
      "last_update_posted_date": "2025-08-07",
      "last_synced_at": "2026-10-10T01:25:19.034Z",
      "location_count": 6,
      "location_summary": "Tampa, Florida • Baltimore, Maryland • Boston, Massachusetts + 3 more",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02269280"
    },
    {
      "nct_id": "NCT07096297",
      "title": "Luspatercept + Darbepoetin in MDS",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "MDS (Myelodysplastic Syndrome)"
      ],
      "interventions": [
        {
          "name": "Luspatercept",
          "type": "DRUG"
        },
        {
          "name": "Darbeopoetin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2025-12-16",
      "completion_date": "2030-08",
      "has_results": false,
      "last_update_posted_date": "2026-09-14",
      "last_synced_at": "2026-10-10T01:25:19.034Z",
      "location_count": 4,
      "location_summary": "New Haven, Connecticut • Chicago, Illinois • Columbus, Ohio + 1 more",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07096297"
    }
  ]
}